, Drug Insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease, Nature Clinical Practice Neurology, vol.20, issue.7, pp.382-392, 2006.
DOI : 10.1038/ncpneuro0222
, Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?, Movement Disorders, vol.54, issue.1, pp.1-9, 2007.
DOI : 10.1002/mds.21060
, Preventing and controlling dyskinesia in Parkinson's disease-A view of current knowledge and future opportunities, Movement Disorders, vol.445, issue.Part 12, pp.585-598, 2008.
DOI : 10.1002/mds.22022
, Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression, JAMA, vol.287, issue.13, pp.1653-1661, 2002.
DOI : 10.1001/jama.287.13.1653
, Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study, Annals of Neurology, vol.43, issue.1, pp.93-101, 2003.
DOI : 10.1002/ana.10609
, Rationale for delayed-start study of pramipexole in Parkinson's disease: The PROUD study, Movement Disorders, vol.61, issue.Suppl 2, pp.1627-1632, 2010.
DOI : 10.1002/mds.23143
, Immediate vs. delayed-start pramipexole in early ParkinsonÕs disease: the PROUD study, XVII WFN World Congress on ParkinsonÕs Disease and Related Disorders, 2010.
, A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease, New England Journal of Medicine, vol.361, issue.13, pp.1268-1278, 2009.
DOI : 10.1056/NEJMoa0809335
, Suboptimal medication adherence in Parkinson's disease, Movement Disorders, vol.34, issue.11, pp.1502-1507, 2005.
DOI : 10.1002/mds.20602
, Drug adherence in Parkinson's disease, Movement Disorders, vol.14, issue.5, pp.513-517, 2004.
DOI : 10.1002/mds.20041
, Problems with long-term levodopa therapy for ParkinsonÕs disease, Clin Neuropharmacol, vol.17, pp.32-44, 1994.
, Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment, The Lancet Neurology, vol.8, issue.5, pp.464-474, 2009.
DOI : 10.1016/S1474-4422(09)70068-7
, Molecular mechanisms of L-DOPA-induced dyskinesia, Nature Reviews Neuroscience, vol.68, issue.9, pp.665-677, 2008.
DOI : 10.1038/nrn2471
, The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease, Parkinsonism & Related Disorders, vol.15, pp.9-15, 2009.
DOI : 10.1016/S1353-8020(09)70005-7
, De novo administration of ropinirole and bromocriptine induces less dyskinesia thanL-dopa in the MPTP-treated marmoset, Movement Disorders, vol.43, issue.2, pp.234-241, 1998.
DOI : 10.1002/mds.870130207
, Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-na??ve primates, Movement Disorders, vol.53, issue.Pt 9, pp.306-314, 2005.
DOI : 10.1002/mds.20317
, Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study, Annals of Neurology, vol.24, issue.21 suppl 4, pp.18-27, 2010.
DOI : 10.1002/ana.22060
, Early Treatment of Parkinson??s Disease with Cabergoline Delays the Onset of Motor Complications, Drugs, vol.55, issue.Supplement 1, pp.23-30, 1998.
DOI : 10.2165/00003495-199855001-00004
, A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa, New England Journal of Medicine, vol.342, issue.20, pp.1484-1491, 2000.
DOI : 10.1056/NEJM200005183422004
, Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease, JAMA, vol.284, issue.15, pp.1931-1938, 2000.
DOI : 10.1001/jama.284.15.1931
, Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4- year randomized controlled trial, Arch Neurol, vol.61, pp.1044-1053, 2004.
, Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study, Movement Disorders, vol.18, issue.Suppl., pp.343-353, 2006.
DOI : 10.1002/mds.20724
, Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease, Journal of Neurology, Neurosurgery & Psychiatry, vol.64, issue.5, pp.573-576, 1998.
DOI : 10.1136/jnnp.64.5.573
, Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease, Neurology, vol.64, issue.2, pp.216-223, 2005.
DOI : 10.1212/01.WNL.0000149637.70961.4C
, Adherence to antiparkinson medication in a multicenter European study, Movement Disorders, vol.20, issue.6, pp.826-832, 2009.
DOI : 10.1002/mds.22112
, Levodopa-induced sleepiness in the Parkinson variant of multiple system atrophy, Movement Disorders, vol.38, issue.8, pp.1281-1283, 2006.
DOI : 10.1002/mds.20898
, A reassessment of risks and benefits of dopamine agonists in Parkinson's disease, The Lancet Neurology, vol.8, issue.10, pp.929-937, 2009.
DOI : 10.1016/S1474-4422(09)70225-X
, Population In Vitro-In Vivo Correlation Model for Pramipexole Slow-Release Oral Formulations, Pharmaceutical Research, vol.52, issue.2, pp.340-349, 2010.
DOI : 10.1007/s11095-009-0027-8
, Pharmacokinetics of a Once-Daily extended-release formulation of pramipexole in healthy male volunteers: Three studies, Clinical Therapeutics, vol.31, issue.11, pp.2698-2711, 2009.
DOI : 10.1016/j.clinthera.2009.10.018
, Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease, Movement Disorders, vol.20, issue.Suppl 1, pp.2542-2549, 2010.
DOI : 10.1002/mds.23317
, Efficacy and safety of pramipexole extended-release for advanced ParkinsonÕs disease, p.199, 2009.
, Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease, Movement Disorders, vol.23, issue.Suppl 3, pp.2326-2332, 2010.
DOI : 10.1002/mds.23262